# Budd-Chiari Syndrome

Budd-Chiari syndrome requires urgent confirmation of hepatic venous outflow obstruction, immediate anticoagulation when feasible, systematic identification of thrombophilia or secondary obstruction, and rapid escalation to endovascular decompression, TIPS, or transplantation when hepatic dysfunction or portal-hypertension complications progress.

**Clinical question:** How should physicians confirm, classify, and manage Budd-Chiari syndrome from initial presentation through endovascular or transplant escalation?

Updated: 2026-08-24T17:25:00.272460+00:00

## What matters in practice
- Treat suspected primary Budd-Chiari syndrome as a hepatic venous outflow emergency: obtain vascular imaging, assess liver failure and portal-hypertension complications, begin anticoagulation when feasible, and evaluate for an underlying hypercoagulable disorder. [10][18][20]
- Doppler ultrasound is an appropriate initial study; contrast-enhanced CT or MR venography should define hepatic-vein and IVC anatomy, collateral pathways, associated portal-vein thrombosis, and an obstructing tumor or other secondary cause. [10][24]
- Distinguish primary thrombotic obstruction from secondary Budd-Chiari syndrome caused by tumor invasion, post-transplant or post-resection injury, extrinsic compression, or rare infiltrative disease because treatment must address the structural cause as well as thrombosis. [10][11]
- Escalate beyond anticoagulation for worsening liver function, refractory ascites, or encephalopathy; selected focal venous lesions may be recanalized, whereas TIPS provides alternative outflow when decompression is needed or recanalization fails. [13][20]
- Refer early for liver-transplant evaluation in fulminant liver failure, acute-on-chronic liver failure, failure of portosystemic shunting or medical management, or hepatocellular carcinoma in chronic Budd-Chiari syndrome. [10]

## Identify patients who need urgent decompression or transplant evaluation

Severity determines the speed of vascular intervention rather than the diagnosis alone.

Urgently assess for acute liver failure, acute-on-chronic liver failure, rapidly worsening synthetic dysfunction, encephalopathy, tense or recurrent ascites, renal dysfunction, and gastrointestinal bleeding. Budd-Chiari syndrome can present as fulminant liver failure; hepatic venous outflow obstruction causes congestion, hepatic dysfunction, and occasionally liver failure. [10][18]

Admit patients with hepatic failure, progressive encephalopathy, worsening ascites, or declining liver function to a center with hepatology, interventional radiology, and transplant capability. Failure of anticoagulation-based management marked by worsening liver function, ascites, or encephalopathy should trigger consideration of endovascular therapy, TIPS, and/or transplant evaluation rather than continued medical observation. [20]

Treat portal-hypertension complications concurrently while defining venous anatomy. Ascites and encephalopathy are clinically consequential manifestations of portal hypertension and advanced liver disease; recurrent or refractory complications favor expedited decompressive intervention rather than delayed etiologic testing alone. [11][20]
- Obtain CBC with platelet count, comprehensive metabolic panel, bilirubin, albumin, creatinine, INR, and serial assessments of encephalopathy and ascites to establish liver injury and trajectory. Liver dysfunction and INR are incorporated into reported Budd-Chiari acute liver failure and prognostic assessments. [10]
- Use urgent vascular imaging when abdominal pain, ascites, hepatomegaly, unexplained hepatic dysfunction, or portal-hypertension features coexist with thrombocytosis, erythrocytosis, leukocytosis, pregnancy exposure, estrogen exposure, inflammatory disease, malignancy, or prior thrombosis. [5][20]

*Clinical findings that should accelerate multidisciplinary intervention in Budd-Chiari syndrome. [10][18][20]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Fulminant liver failure or acute-on-chronic liver failure | Potentially life-threatening hepatic venous outflow obstruction. [10][18] | Urgent hepatology, interventional radiology, and transplant-center evaluation. [10][20] |
| Worsening liver function, ascites, or encephalopathy despite anticoagulation | Failure of medical management requiring decompressive strategy assessment. [20] | Assess feasibility of venous recanalization; consider TIPS and transplant evaluation. [13][20] |
| Portal-vein extension or complex splanchnic thrombosis | May complicate hepatic venous obstruction and influence intervention planning. [12][14] | Define portal and mesenteric venous anatomy on contrast imaging and involve experienced interventional radiology. [14][24] |

## Confirm hepatic venous outflow obstruction and map the target for intervention

Imaging must establish both the diagnosis and the anatomy that determines recanalization versus shunting.

Diagnose Budd-Chiari syndrome when imaging demonstrates obstruction of hepatic venous outflow from the hepatic venules through the hepatic-vein/IVC junction, without an intracardiac or pericardial cause. Obstruction may involve small hepatic veins, major hepatic veins, or the hepatic portion of the IVC. [10][11][17]

Use Doppler ultrasound as the first vascular test. Findings supporting Budd-Chiari syndrome include poor visualization or nonvisualization of hepatic veins, abnormal hepatic-vein flow, collapsed suprahepatic veins, and loss of visualization at the hepatic vein-IVC junction. If ultrasound is equivocal or intervention is contemplated, obtain contrast-enhanced CT or MR venography to define thrombosis or stenosis, IVC involvement, collateral vessels, caudate hypertrophy, and liver enhancement pattern. [24]

Use CT or MR venography to distinguish a focal hepatic-vein or IVC lesion potentially amenable to recanalization from diffuse hepatic-vein occlusion more likely to require TIPS. CT and MRI also identify portal-, splenic-, or superior mesenteric-vein thrombosis, which can coexist with Budd-Chiari syndrome and materially affects procedural planning. [12][13][14][24]

Do not rely on liver biopsy to establish the vascular diagnosis when imaging is diagnostic. Biopsy may support assessment of liver injury or alternative pathology, but histology is not pathognomonic and varies across patients. Reserve it for unresolved diagnostic questions or when tissue will change management. [8][24]
- Actively exclude right-sided cardiac or pericardial causes of hepatic congestion before labeling a patient with Budd-Chiari syndrome, because the defining diagnosis excludes intracardiac and pericardiac obstruction. [10]
- Evaluate an IVC lesion as part of the disease spectrum rather than assuming congenital membranous obstruction; obliterative disease of the hepatic IVC has been described as a thrombosis sequela. [17]
- When a hepatic or portal venous filling defect is present, evaluate enhancement and vessel expansion to distinguish tumor thrombus from bland thrombus; arterial-phase enhancement, portal-vein expansion, and high diffusion-weighted MR signal favor tumor-related portal-vein thrombosis. [2]

*Imaging-driven anatomic classification and immediate implication. [10][13][17][24]*

| Imaging pattern | Likely interpretation | Management implication |
| --- | --- | --- |
| Hepatic-vein thrombosis or stenosis with defined focal target | Primary hepatic venous outflow obstruction may be anatomically suitable for restoration of patency. [10][20] | Discuss endovascular recanalization or angioplasty/stenting with interventional radiology while continuing anticoagulation when feasible. [20] |
| Hepatic IVC obstruction with hepatic-vein ostial disease | Hepatic IVC thrombosis/obliterative disease may coexist with hepatic-vein obstruction. [17] | Map the IVC and hepatic-vein ostia for reconstructive endovascular planning; TIPS may be required if hepatic-vein recanalization fails. [13] |
| Diffuse hepatic-vein occlusion or failed recanalization | Direct restoration of hepatic venous drainage may not be feasible. [13] | Consider TIPS to create alternative venous outflow. [13][20] |
| Mass invasion, external compression, or post-surgical vascular injury | Secondary Budd-Chiari syndrome. [10] | Treat the causative structural process and assess whether anticoagulation or vascular intervention is also indicated. [10] |

## Separate primary thrombosis from secondary obstruction and investigate thrombophilia

Etiologic testing should proceed in parallel with anticoagulation and anatomic planning.

Classify disease as primary when hepatic venous outflow obstruction is thrombotic and as secondary when obstruction results from malignant invasion, post-transplant or post-resection hepatic-vein injury, extrinsic compression from hydatid cysts or polycystic liver disease, or rarely sarcoidosis. This distinction directs treatment toward systemic thrombosis prevention versus correction or treatment of the local cause. [10][11]

Evaluate every patient for an underlying hypercoagulable condition. Myeloproliferative disorders are prominent acquired causes, and thrombocytosis, erythrocytosis, or leukocytosis should heighten suspicion; the AASLD clinical example specifically links this phenotype to hypercoagulable evaluation. [5][20]

Obtain a thrombophilia-focused evaluation that includes assessment for myeloproliferative neoplasm, antiphospholipid antibodies, factor V Leiden, prothrombin G20210A, antithrombin deficiency, protein C deficiency, and protein S deficiency. Evaluate acquired exposures and conditions including pregnancy, oral contraceptive use, inflammatory bowel disease, tumor, and bacterial or fungal infection. Multiple prothrombotic factors may coexist, particularly when other splanchnic veins are thrombosed. [5][12]

For suspected myeloproliferative neoplasm, test for JAK2 V617F and coordinate hematology assessment even when hepatic congestion or portal hypertension complicates interpretation of blood counts. JAK2 V617F has a recognized association with Budd-Chiari syndrome, and chronic myeloproliferative disorders are established acquired thrombotic risk factors. [5][9][20]
- Review estrogen-containing medications, pregnancy status, inflammatory bowel disease activity, cancer history, infection, prior venous thromboembolism, and family history before concluding that thrombosis is idiopathic. [5]
- Inspect contrast-enhanced imaging for hepatic or extrahepatic malignancy and for tumor-related venous invasion; a malignancy-associated obstruction is secondary Budd-Chiari syndrome and requires oncologic as well as vascular planning. [10][12]
- If portal-vein thrombosis is present in a patient with cirrhosis or suspected HCC, distinguish bland from tumor thrombus before selecting a thrombosis-focused strategy. [2]

*Etiologic branches that change management in Budd-Chiari syndrome. [5][10][12]*

| Etiologic branch | Clinical or test clue | Management consequence |
| --- | --- | --- |
| Myeloproliferative neoplasm | Thrombocytosis, erythrocytosis, leukocytosis, or JAK2 V617F positivity. [5][9][20] | Coordinate hematology-directed disease management while maintaining thrombosis prevention and venous-outflow treatment. [20] |
| Inherited or acquired thrombophilia | Factor V Leiden, prothrombin G20210A, antithrombin, protein C, protein S deficiency, or antiphospholipid antibodies. [5] | Anticoagulation and long-term thrombosis-prevention planning must account for the identified disorder. [11][20] |
| Hormonal, pregnancy, inflammatory, infectious, or malignant trigger | Oral contraceptive exposure, pregnancy, inflammatory bowel disease, infection, or tumor. [5] | Remove or treat the provoking condition while managing hepatic-vein obstruction. [5][10] |
| Secondary mechanical obstruction | Tumor invasion, surgical injury, hydatid cyst, polycystic liver disease, or sarcoidosis. [10] | Address the structural disease; do not treat as isolated primary thrombosis. [10] |

## Use anticoagulation first, then restore outflow or decompress the liver

Treatment proceeds in parallel tracks: stop thrombus propagation, correct the cause, and relieve venous congestion.

Initiate therapeutic anticoagulation in Budd-Chiari syndrome while evaluating anatomy and underlying thrombophilia, unless a patient-specific contraindication requires modification. Therapeutic anticoagulation is described as first-line treatment for Budd-Chiari syndrome, and anticoagulation should begin while other therapeutic options are explored. [11][20]

Do not use clinical stability after anticoagulation as the only endpoint. Reassess liver function, ascites, and encephalopathy; clinical deterioration despite anticoagulation indicates failure of medical management and should prompt endovascular and transplant discussion. [20]

When a thrombosed or stenotic hepatic vein has a treatable focal lesion, pursue restoration of patency with endovascular recanalization, angioplasty, and, when appropriate, stenting. In contrast, if hepatic-vein recanalization fails, TIPS can provide an alternative route for hepatic venous outflow. [13][20]

Use TIPS for patients who require decompression because of persistent portal-hypertension complications, worsening liver function, or anatomy unsuitable for recanalization. TIPS is commonly used in Budd-Chiari syndrome and remains effective even when thrombosis extends into the portal venous tree, although complex thrombosis requires experienced procedural planning. [14][20]

Refer for liver transplantation when fulminant liver failure, acute-on-chronic liver failure, failure of medical therapy and portosystemic shunting, or hepatocellular carcinoma complicates chronic Budd-Chiari syndrome. Long-term anticoagulation is required in most transplanted patients because thrombosis can recur. [10]
- Treat the associated prothrombotic disorder rather than considering venous intervention definitive therapy; recurrent thrombosis can occur in hypercoagulable patients, including within TIPS or the IVC. [13]
- For secondary Budd-Chiari syndrome, pair anticoagulation decisions with treatment of tumor, external compression, or iatrogenic vascular injury. [10]
- Use a multidisciplinary plan involving hepatology, hematology, interventional radiology, and transplant surgery when hepatic dysfunction progresses or complex IVC/portal venous involvement is present. [10][13][20]

### Procedure selection

Choose recanalization when imaging identifies an accessible focal hepatic-vein or IVC obstruction that can restore physiologic drainage. Choose TIPS when recanalization is unsuccessful or inadequate, particularly when progressive congestion or portal-hypertension complications require prompt decompression. [13][20]

Reserve transplantation for liver failure or failed decompressive strategies rather than delaying referral until irreversible decompensation. Transplantation is also an indicated consideration when chronic Budd-Chiari syndrome is complicated by liver cancer. [10]

*Stepwise treatment selection in Budd-Chiari syndrome. [10][11][13][20]*

| Treatment step | When to use | Key limitation or escalation trigger |
| --- | --- | --- |
| Therapeutic anticoagulation | Initiate during evaluation of suspected or confirmed Budd-Chiari syndrome when feasible. [11][20] | Worsening liver function, ascites, or encephalopathy requires reassessment for intervention. [20] |
| Venous recanalization, angioplasty, or stenting | Focal thrombosed or stenotic hepatic-vein/IVC lesion with suitable anatomy. [13][20] | Failed or infeasible hepatic-vein recanalization favors TIPS. [13] |
| TIPS | Need for alternative outflow after failed recanalization or progressive clinical decompensation. [13][20] | Persistent failure or liver failure requires transplant assessment. [10][20] |
| Liver transplantation | Fulminant liver failure, acute-on-chronic liver failure, failed medical/shunt therapy, or HCC in chronic disease. [10] | Most patients still require long-term anticoagulation because thrombosis may recur. [10] |

## Monitor for recurrent thrombosis, shunt dysfunction, decompensation, and liver cancer

Follow-up must assess both vascular patency and the underlying thrombotic disease.

After anticoagulation, recanalization, or TIPS, follow clinical congestion and hepatic function with serial assessment of ascites, encephalopathy, bilirubin, INR, creatinine, and blood counts. Recurrent ascites or worsening encephalopathy should prompt reassessment for persistent obstruction, TIPS dysfunction, progressive liver disease, or recurrent thrombosis. [10][20][21]

Maintain surveillance for thrombosis recurrence in patients with underlying hypercoagulability and after TIPS. Hypercoagulable patients with primary Budd-Chiari syndrome are predisposed to new thrombosis in the TIPS shunt or IVC, making ongoing anticoagulation strategy and vascular follow-up central to management. [13]

In chronic Budd-Chiari syndrome, evaluate new liver lesions with multiphasic contrast imaging. Portal-vein tumor invasion is prognostically important in HCC; arterial-phase enhancement within thrombus, portal-vein expansion, and high diffusion-weighted MR signal favor tumor thrombus over bland thrombosis. [2][10]
- Re-engage hematology when blood counts evolve, JAK2 V617F is detected, or recurrent thrombosis occurs despite vascular intervention. [5][9][20]
- Reassess transplant candidacy after failure of TIPS or progressive hepatic dysfunction rather than treating shunt placement as the endpoint of care. [10]
- When portal-vein thrombosis accompanies chronic liver disease, characterize tumor versus bland thrombus because tumor invasion narrows treatment options and worsens prognosis. [2]

*Follow-up triggers requiring a change in management. [2][10][13][20]*

| Follow-up finding | Concern | Next step |
| --- | --- | --- |
| Recurrent ascites, encephalopathy, or worsening liver function | Persistent venous congestion, shunt dysfunction, or hepatic decompensation. [20][21] | Repeat vascular and liver assessment; reconsider TIPS revision strategy or transplant evaluation. [10][20] |
| New thrombosis after TIPS or IVC intervention | Ongoing hypercoagulable state and device-associated vascular risk. [13] | Reassess anticoagulation and underlying thrombophilia with hematology and interventional radiology. [13][20] |
| Enhancing portal-vein thrombus or vessel expansion | Tumor-related portal-vein invasion. [2] | Stage for HCC and differentiate from bland thrombosis before further vascular treatment decisions. [2] |

## References
1. HEPATOCELLULAR CARCINOMA IN BUDD-CHIARI ... - Gut — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2008/01/24/gut.2007.139477.full.pdf
2. British Society of Gastroenterology guidelines for the ... — gut.bmj.com — https://gut.bmj.com/content/gutjnl/early/2024/04/29/gutjnl-2023-331695.full.pdf
3. Protected by copyright, including for uses related to text and data ... — gut.bmj.com — https://gut.bmj.com/content/gutjnl/55/6/884.full.pdf
4. Successful treatment of extensive splanchnic vein ... — casereports.bmj.com — https://casereports.bmj.com/content/2018/bcr-2017-222710.full.pdf
5. a rare and life-threatening complication of Crohn's disease — casereports.bmj.com — https://casereports.bmj.com/content/2018/bcr-2017-222946.full.pdf
6. Budd-Chiari syndrome: a rare and life-threatening ... — casereports.bmj.com — https://casereports.bmj.com/content/2018/bcr-2017-222946
7. Successful Treatment by Percutaneous Balloon ... — www.jacc.org — https://www.jacc.org/doi/10.1016/S0735-1097%2896%2900385-3
8. Budd–Chiari syndrome: a review by an expert panel - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0168827802004348
9. Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0168827819301308
10. Budd-Chiari Syndrome: Presentation, Management, and... : Official journal of the American College of Gastroenterology | ACG — journals.lww.com — https://journals.lww.com/ajg/fulltext/9900/budd_chiari_syndrome__presentation,_management,.2032.aspx
11. Management of portal hypertension, Budd– Chiari syndrome and portal vein thrombosis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1357303923000804
12. Portal Vein Thrombosis and Budd–Chiari Syndrome - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0889858811001080
13. Recanalization and Reconstruction of a... : Vascular and Endovascular Surgery — journals.lww.com — https://journals.lww.com/00134449-202155050-00018
14. Budd-chiari syndrome management: Timing of... : Hepatology — journals.lww.com — https://journals.lww.com/hep/fulltext/2014/03000/budd_chiari_syndrome_management__timing_of.54.aspx
15. Budd-Chiari Syndrome in Children — journals.lww.com — https://journals.lww.com/jpgn/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005176-201001000-00019
16. Budd-Chiari Syndrome: Update on Classification and ... — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/rg.240240
17. Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/9794901
18. Chapter 16: Atypical-site thrombosis - ASH Publications — ashpublications.org — https://ashpublications.org/books/book/10/chapter/12744671/Atypical-site-thrombosis
19. Clots in unusual places: lots of stress, limited data, critical ... — ashpublications.org — https://ashpublications.org/hematology/article/2021/1/92/482935/Clots-in-unusual-places-lots-of-stress-limited
20. An 'Ascite-ing' Case of Abdominal Distention | AASLD — www.aasld.org — https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/ascite-ing-case-abdominal-distention
21. Long-term Outcome and Analysis of Dysfunction ... — pubs.rsna.org — https://pubs.rsna.org/doi/10.1148/radiol.2016152641
22. Microbubble-enhanced US in Body Imaging: What Role? — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/radiol.10091210
23. MR Imaging of Hepatocellular Carcinoma in the Cirrhotic ... — pubs.rsna.org — https://pubs.rsna.org/doi/abs/10.1148/radiol.2472061331
24. Budd-Chiari syndrome in a 33-year-old woman with hypercoagulable state: A case report — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12018093

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.